Last update 01 Nov 2024

ENPP3 x Tubulin

Last update 01 Nov 2024

Basic Info

Related Targets

ENPP3Tubulin

Drugs associated with ENPP3 x Tubulin

AGS-16C3F

Target

ENPP3 x Tubulin

Mechanism

ENPP3 inhibitors [+1]

Active Org.-

Originator Org.

Agensys, Inc.

Active Indication-

Inactive Indication

Advanced Renal Cell Carcinoma [+2]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with ENPP3 x Tubulin

NCT02639182 / CompletedPhase 2

A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Start Date03 May 2016

Sponsor / Collaborator

Astellas Pharma Global Development, Inc.

NCT01672775 / CompletedPhase 1

A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).

Start Date18 Jul 2012

Sponsor / Collaborator

Agensys, Inc.

NCT01114230 / CompletedPhase 1

A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma

The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.

Start Date01 Aug 2010

Sponsor / Collaborator

Astellas Pharma, Inc.

[+1]

100 Clinical Results associated with ENPP3 x Tubulin

100 Translational Medicine associated with ENPP3 x Tubulin

0 Patents (Medical) associated with ENPP3 x Tubulin

Literatures (Medical) associated with ENPP3 x Tubulin

01 Nov 2012·GutQ1 · MEDICINE

ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis

Q1 · MEDICINE

Article

Author: Ragnhild A. Lothe ; Arild Nesbakken ; Guro E. Lind ; Rolf I. Skotheim ; Anita Sveen ; Marianne A. Merok ; Trude H. Ågesen

BACKGROUND AND AIMSSeveral clinical factors have an impact on prognosis in stage II colorectal cancer (CRC), but as yet they are inadequate for risk assessment. The present study aimed to develop a gene expression classifier for improved risk stratification of patients with stage II CRC.METHODS315 CRC samples were included in the study. Gene expression measurements from 207 CRC samples (stage I-IV) from two independent Norwegian clinical series were obtained using Affymetrix exon-level microarrays. Differentially expressed genes between stage I and stage IV samples from the test series were identified and used as input for L1 (lasso) penalised Cox proportional hazards analyses of patients with stage II CRC from the same series. A second validation was performed in 108 stage II CRC samples from other populations (USA and Australia).RESULTSAn optimal 13-gene expression classifier (PIGR, CXCL13, MMP3, TUBA1B, SESN1, AZGP1, KLK6, EPHA7, SEMA3A, DSC3, CXCL10, ENPP3, BNIP3) for prediction of relapse among patients with stage II CRC was developed using a consecutive Norwegian test series from patients treated according to current standard protocols (n=44, p<0.001, HR=18.2), and its predictive value was successfully validated for patients with stage II CRC in a second Norwegian CRC series collected two decades previously (n=52, p=0.02, HR=3.6). Further validation of the classifier was obtained in a recent external dataset of patients with stage II CRC from other populations (n=108, p=0.001, HR=6.5). Multivariate Cox regression analyses, including all three sample series and various clinicopathological variables, confirmed the independent prognostic value of the classifier (p≤0.004). The classifier was shown to be specific to stage II CRC and does not provide prognostic stratification of patients with stage III CRC.CONCLUSIONThis study presents the development and validation of a 13-gene expression classifier, ColoGuideEx, for prognosis prediction specific to patients with stage II CRC. The robustness was shown across patient series, populations and different microarray versions.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis